Unknown

Dataset Information

0

Mast Cells in Alveolar Septa of COVID-19 Patients: A Pathogenic Pathway That May Link Interstitial Edema to Immunothrombosis.


ABSTRACT: It is currently believed that innate immunity is unable to prevent the spread of SARS-CoV-2 from the upper airways to the alveoli of high-risk groups of patients. SARS-CoV-2 replication in ACE-2-expressing pneumocytes can drive the diffuse alveolar injury through the cytokine storm and immunothrombosis by upregulating the transcription of chemokine/cytokines, unlike several other respiratory viruses. Here we report histopathology data obtained in post-mortem lung biopsies of COVID-19, showing the increased density of perivascular and septal mast cells (MCs) and IL-4-expressing cells (n = 6), in contrast to the numbers found in pandemic H1N1-induced pneumonia (n = 10) or Control specimens (n = 10). Noteworthy, COVID-19 lung biopsies showed a higher density of CD117+ cells, suggesting that c-kit positive MCs progenitors were recruited earlier to the alveolar septa. These findings suggest that MC proliferation/differentiation in the alveolar septa might be harnessed by the shift toward IL-4 expression in the inflamed alveolar septa. Future studies may clarify whether the fibrin-dependent generation of the hyaline membrane, processes that require the diffusion of procoagulative plasma factors into the alveolar lumen and the endothelial dysfunction, are preceded by MC-driven formation of interstitial edema in the alveolar septa.

SUBMITTER: Motta Junior JDS 

PROVIDER: S-EPMC7530169 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Mast Cells in Alveolar Septa of COVID-19 Patients: A Pathogenic Pathway That May Link Interstitial Edema to Immunothrombosis.

Motta Junior Jarbas da Silva JDS   Miggiolaro Anna Flavia Ribeiro Dos Santos AFRDS   Nagashima Seigo S   de Paula Caroline Busatta Vaz CBV   Baena Cristina Pellegrino CP   Scharfstein Julio J   de Noronha Lucia L  

Frontiers in immunology 20200918


It is currently believed that innate immunity is unable to prevent the spread of SARS-CoV-2 from the upper airways to the alveoli of high-risk groups of patients. SARS-CoV-2 replication in ACE-2-expressing pneumocytes can drive the diffuse alveolar injury through the cytokine storm and immunothrombosis by upregulating the transcription of chemokine/cytokines, unlike several other respiratory viruses. Here we report histopathology data obtained in post-mortem lung biopsies of COVID-19, showing th  ...[more]

Similar Datasets

| S-EPMC8023349 | biostudies-literature
| S-EPMC8596655 | biostudies-literature
| S-EPMC10432277 | biostudies-literature
| S-EPMC7753335 | biostudies-literature
| S-EPMC10193231 | biostudies-literature
| S-EPMC10825058 | biostudies-literature
| S-EPMC7472714 | biostudies-literature
| S-EPMC2584714 | biostudies-literature
2023-04-11 | GSE225054 | GEO
| S-EPMC4390504 | biostudies-literature